Magnetic resonance imaging of glioma in the era of antiangiogenic therapy

PET Clinics

Volumn 8, Issue 2, 2013, Pages 163-182

  Khan, Sarah N ^a   Linetsky, Michael ^a   Ellingson, Benjamin M ^a   Pope, Whitney B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bevacizumab; Diffusion; Glioblastoma; Glioma; MR imaging; Perfusion; Response evaluation; Spectroscopy

Indexed keywords

BEVACIZUMAB; FERUMOXYTOL; GADOLINIUM; GADOTERIDOL; TEMOZOLOMIDE;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; BRAIN BLOOD FLOW; BRAIN EDEMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; GLIOBLASTOMA; GLIOSIS; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR RECURRENCE;

EID: 84875724454     PISSN: 15568598     EISSN: 18799809     Source Type: Journal    
DOI: 10.1016/j.cpet.2012.09.004     Document Type: Review

References (70)

1. N.O. Schmidt, M. Westphal, and C. Hagel Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis Int J Cancer 84 1 1999 10 18
2. J. Holash, P.C. Maisonpierre, and D. Compton Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF Science 284 5422 1999 1994 1998
3. K.H. Plate, G. Breier, and H.A. Weich Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo Nature 359 6398 1992 845 848
4. S. Soker, H. Fidder, and G. Neufeld Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain J Biol Chem 271 10 1996 5761 5767
5. J. Oliner, H. Min, and J. Leal Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 Cancer Cell 6 5 2004 507 516
6. R.S. Kerbel Tumor angiogenesis N Engl J Med 358 19 2008 2039 2049
7. J.W. Henson, S. Ulmer, and G.J. Harris Brain tumor imaging in clinical trials AJNR Am J Neuroradiol 29 3 2008 419 424
8. D.R. Macdonald, T.L. Cascino, and S.C. Schold Jr. Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 7 1990 1277 1280
9. WHO Handbook for reporting results of cancer treatment 1979 World Health Organization Offset Publication Geneva (Switzerland) 48
10. A.B. Miller, B. Hoogstraten, and M. Staquet Reporting results of cancer treatment Cancer 47 1 1981 207 214
11. D. Brandsma, L. Stalpers, and W. Taal Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas Lancet Oncol 9 5 2008 453 461
12. M.C. Chamberlain, M.J. Glantz, and L. Chalmers Early necrosis following concurrent temodar and radiotherapy in patients with glioblastoma J Neurooncol 82 1 2007 81 83
13. M.C. de Wit, H.G. de Bruin, and W. Eijkenboom Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression Neurology 63 3 2004 535 537
14. W. Taal, D. Brandsma, and H.G. de Bruin Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide Cancer 113 2 2008 405 410
15. P.Y. Wen, D.R. Macdonald, and D.A. Reardon Updated response assessment criteria for high-grade gliomas: Response Assessment In Neuro-Oncology working group J Clin Oncol 28 11 2010 1963 1972
16. T.T. Batchelor, A.G. Sorensen, and E. di Tomaso AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients Cancer Cell 11 1 2007 83 95
17. H.S. Friedman, M.D. Prados, and P.Y. Wen Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 28 2009 4733 4740
18. J.J. Vredenburgh, A. Desjardins, and J.E. Herndon 2nd Bevacizumab plus irinotecan in recurrent glioblastoma multiforme J Clin Oncol 25 30 2007 4722 4729
19. A.D. Norden, J. Drappatz, and A. Muzikansky An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma J Neurooncol 92 2 2009 149 155
20. J.F. de Groot, G. Fuller, and A.J. Kumar Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice Neuro Oncol 12 3 2010 233 242
21. G. Auf, A. Jabouille, and S. Guerit Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma Proc Natl Acad Sci U S A 107 35 2010 15553 15558
22. A.D. Norden, G.S. Young, and K. Setayesh Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence Neurology 70 10 2008 779 787
23. A. Claes, A.J. Idema, and P. Wesseling Diffuse glioma growth: a guerilla war Acta Neuropathol 114 5 2007 443 458
24. W.B. Pope, Q. Xia, and V.E. Paton Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab Neurology 76 5 2011 432 437
25. M.C. Chamberlain Radiographic patterns of relapse in glioblastoma J Neurooncol 101 2 2011 319 323
26. H.J. Aronen, I.E. Gazit, and D.N. Louis Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings Radiology 191 1 1994 41 51
27. S. Cha, E.A. Knopp, and G. Johnson Dynamic contrast-enhanced T2-weighted MR imaging of recurrent malignant gliomas treated with thalidomide and carboplatin AJNR Am J Neuroradiol 21 5 2000 881 890
28. R.G. Henry, D.B. Vigneron, and N.J. Fischbein Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas AJNR Am J Neuroradiol 21 2 2000 357 366
29. J.M. Lupo, S. Cha, and S.M. Chang Dynamic susceptibility-weighted perfusion imaging of high-grade gliomas: characterization of spatial heterogeneity AJNR Am J Neuroradiol 26 6 2005 1446 1454
30. J.L. Boxerman, D.E. Prah, and E.S. Paulson The role of preload and leakage correction in gadolinium-based cerebral blood volume estimation determined by comparison with MION as a criterion standard AJNR Am J Neuroradiol 33 6 2012 1081 1087
31. L.S. Hu, L.C. Baxter, and D.S. Pinnaduwage Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomas AJNR Am J Neuroradiol 31 1 2010 40 48
32. E.S. Paulson, and K.M. Schmainda Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors Radiology 249 2 2008 601 613
33. J.L. Boxerman, K.M. Schmainda, and R.M. Weisskoff Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not AJNR Am J Neuroradiol 27 4 2006 859 867
34. C.C. Quarles, B.D. Ward, and K.M. Schmainda Improving the reliability of obtaining tumor hemodynamic parameters in the presence of contrast agent extravasation Magn Reson Med 53 6 2005 1307 1316
35. T. Hirai, R. Murakami, and H. Nakamura Prognostic value of perfusion MR imaging of high-grade astrocytomas: long-term follow-up study AJNR Am J Neuroradiol 29 8 2008 1505 1510
36. M. Law, R.J. Young, and J.S. Babb Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging Radiology 247 2 2008 490 498
37. R. Mangla, G. Singh, and D. Ziegelitz Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma Radiology 256 2 2010 575 584
38. R.N. Sawlani, J. Raizer, and S.W. Horowitz Glioblastoma: a method for predicting response to antiangiogenic chemotherapy by using MR perfusion imaging - pilot study Radiology 255 2 2010 622 628
39. N.S. Akella, D.B. Twieg, and T. Mikkelsen Assessment of brain tumor angiogenesis inhibitors using perfusion magnetic resonance imaging: quality and analysis results of a phase I trial J Magn Reson Imaging 20 6 2004 913 922
40. R.F. Barajas Jr., J.S. Chang, and M.R. Segal Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging Radiology 253 2 2009 486 496
41. L.S. Hu, L.C. Baxter, and K.A. Smith Relative cerebral blood volume values to differentiate high-grade glioma recurrence from posttreatment radiation effect: direct correlation between image-guided tissue histopathology and localized dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging measurements AJNR Am J Neuroradiol 30 3 2009 552 558
42. T. Sugahara, Y. Korogi, and S. Tomiguchi Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue AJNR Am J Neuroradiol 21 5 2000 901 909
43. E.L. Gasparetto, M.A. Pawlak, and S.H. Patel Posttreatment recurrence of malignant brain neoplasm: accuracy of relative cerebral blood volume fraction in discriminating low from high malignant histologic volume fraction Radiology 250 3 2009 887 896
44. S. Gahramanov, A.M. Raslan, and L.L. Muldoon Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study Int J Radiat Oncol Biol Phys 79 2 2011 514 523
45. P.S. Tofts, and A.G. Kermode Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts Magn Reson Med 17 2 1991 357 367
46. Y. Cao, C.I. Tsien, and V. Nagesh Survival prediction in high-grade gliomas by MRI perfusion before and during early stage of RT [corrected] Int J Radiat Oncol Biol Phys 64 3 2006 876 885
47. A.G. Sorensen, T.T. Batchelor, and W.T. Zhang A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients Cancer Res 69 13 2009 5296 5300
48. K.E. Emblem, A. Bjornerud, and K. Mouridsen T(1)- and T(2)(*)-dominant extravasation correction in DSC-MRI: part II-predicting patient outcome after a single dose of cediranib in recurrent glioblastoma patients J Cereb Blood Flow Metab 31 10 2011 2054 2064
49. S. Bisdas, T. Naegele, and R. Ritz Distinguishing recurrent high-grade gliomas from radiation injury: a pilot study using dynamic contrast-enhanced MR imaging Acad Radiol 18 5 2011 575 583
50. T.L. Chenevert, L.D. Stegman, and J.M. Taylor Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors J Natl Cancer Inst 92 24 2000 2029 2036
51. 19F spectroscopy and diffusion-weighted MRI to evaluate differences in gene-dependent enzyme prodrug therapies Mol Ther 10 5 2004 916 928
52. D.E. Hall, B.A. Moffat, and J. Stojanovska Therapeutic efficacy of DTI-015 using diffusion magnetic resonance imaging as an early surrogate marker Clin Cancer Res 10 23 2004 7852 7859
53. B.M. Ellingson, M.G. Malkin, and S.D. Rand Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity J Magn Reson Imaging 31 3 2010 538 548
54. T. Sugahara, Y. Korogi, and M. Kochi Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas J Magn Reson Imaging 9 1 1999 53 60
55. H. Lyng, O. Haraldseth, and E.K. Rofstad Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging Magn Reson Med 43 6 2000 828 836
56. Y. Hayashida, T. Hirai, and S. Morishita Diffusion-weighted imaging of metastatic brain tumors: comparison with histologic type and tumor cellularity AJNR Am J Neuroradiol 27 7 2006 1419 1425
57. G. Manenti, M. Di Roma, and S. Mancino Malignant renal neoplasms: correlation between ADC values and cellularity in diffusion weighted magnetic resonance imaging at 3 T Radiol Med 113 2 2008 199 213 [in English, Italian]
58. E.R. Gerstner, M.P. Frosch, and T.T. Batchelor Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab J Clin Oncol 28 6 2010 e91 e93
59. E.R. Gerstner, P.J. Chen, and P.Y. Wen Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib Neuro Oncol 12 5 2010 466 472
60. J. Rieger, O. Bahr, and K. Muller Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients J Neurooncol 99 1 2010 49 56
61. S. Mong, B.M. Ellingson, and P.L. Nghiemphu Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls AJNR Am J Neuroradiol 33 9 2012 1763 1770
62. W.B. Pope, H.J. Kim, and J. Huo Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment Radiology 252 1 2009 182 189
63. D.A. Hamstra, T.L. Chenevert, and B.A. Moffat Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma Proc Natl Acad Sci U S A 102 46 2005 16759 16764
64. D.A. Hamstra, C.J. Galban, and C.R. Meyer Functional diffusion map as an early imaging biomarker for high-grade glioma: correlation with conventional radiologic response and overall survival J Clin Oncol 26 20 2008 3387 3394
65. B.M. Ellingson, T.F. Cloughesy, and T. Zaw Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma Neuro Oncol 14 3 2012 333 343
66. B.M. Ellingson, S.D. Rand, and M.G. Malkin Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri J Neurooncol 97 3 2010 419 423
67. B.M. Ellingson, P.S. LaViolette, and S.D. Rand Spatially quantifying microscopic tumor invasion and proliferation using a voxel-wise solution to a glioma growth model and serial diffusion MRI Magn Reson Med 65 4 2011 1131 1143
68. B.M. Ellingson, T.F. Cloughesy, and A. Lai Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab J Neurooncol 105 1 2011 91 101
69. E.A. Smith, R.C. Carlos, and L.R. Junck Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions AJR Am J Roentgenol 192 2 2009 W45 W52
70. P. Weybright, P.C. Sundgren, and P. Maly Differentiation between brain tumor recurrence and radiation injury using MR spectroscopy AJR Am J Roentgenol 185 6 2005 1471 1476